The world of cancer research is a complex and ever-evolving landscape, and the latest development in the field of non-small cell lung cancer (NSCLC) treatment is a fascinating one. The recent publication in Cancer Cell by Professor Li Zhang and Professor Wenfeng Fang from the Sun Yat-sen University Cancer Center has shed light on a novel approach to delaying EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC. This research, led by Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, introduces a groundbreaking combination therapy that could revolutionize the treatment of advanced EGFR-mutant NSCLC.
The Study: Targeting TROP2 for Resistance Delay
The study, titled 'Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer,' reveals a fascinating mechanism behind drug resistance. The researchers found that trophoblast cell-surface antigen 2 (TROP2) expression is upregulated in residual drug-tolerant persister (DTP) cells after EGFR TKI treatment. This discovery is significant because it provides a potential target for delaying resistance, which is a major challenge in cancer treatment.
In preclinical models, the combination of sacituzumab tirumotecan (sac-TMT) and osimertinib inhibited DTP cell formation and delayed tumor recurrence. This combination therapy, which targets TROP2, has shown promise in delaying drug resistance, a crucial aspect of cancer treatment. The study's findings offer a new perspective on the role of TROP2 in cancer progression and provide a scientific basis for the combination of TROP2-directed antibody drug conjugates (ADCs) and EGFR-TKIs.
Kelun-Biotech's Clinical Development
Building on this research, Kelun-Biotech is advancing a Phase III registrational study of sac-TMT in combination with osimertinib versus osimertinib monotherapy as first-line treatment for locally advanced or metastatic EGFR-mutant non-squamous NSCLC. This study, with enrollment completed in China, aims to evaluate the efficacy and safety of the combination therapy. The company is also exploring earlier-stage NSCLC treatment with a Phase II study evaluating sac-TMT in combination with osimertinib or as monotherapy in the neoadjuvant setting for EGFR-mutant resectable NSCLC.
Sac-TMT: A Novel ADC with Broad Potential
Sac-TMT, a core product of Kelun-Biotech, is a novel human TROP2 ADC with proprietary intellectual property rights. It targets advanced solid tumors, including NSCLC, breast cancer, gastric cancer, and gynecological tumors. The drug's unique bifunctional linker maximizes payload delivery to tumor cells, making it a powerful tool in cancer treatment. Sac-TMT's ability to recognize TROP2 on tumor cell surfaces and release the payload KL610023 intracellularly induces DNA damage, cell-cycle arrest, and apoptosis. Additionally, KL610023 can enable a bystander effect, killing adjacent tumor cells.
Market Approval and Future Prospects
Sac-TMT has already been approved in China for several indications, including unresectable locally advanced or metastatic triple-negative breast cancer, EGFR mutant-positive NSCLC following TKI therapy, and hormone receptor-positive breast cancer. The drug's inclusion in China's National Reimbursement Drug List is expected to benefit a significant number of patients. Kelun-Biotech is also exploring new indications, such as the combination of sac-TMT with pembrolizumab for first-line treatment of locally advanced or metastatic NSCLC with low PD-L1 expression.
In conclusion, the publication in Cancer Cell and Kelun-Biotech's clinical development efforts highlight the potential of targeting TROP2 for delaying drug resistance in NSCLC. Sac-TMT, with its unique mechanism and broad potential, is a promising ADC that could revolutionize the treatment of advanced NSCLC. As the company continues to explore new indications and expand its clinical development, the future of cancer treatment may be brighter, offering more effective and personalized therapies for patients.
